Floatz logo

Monomethyl Fumarate

Juvenile Idiopathic Arthritis (JIA)

National Institute of Allergy and Infectious Diseases (NIAID)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Juvenile Idiopathic Arthritis (JIA) cohort.

Asset / SponsorPhaseRating
Monovalent [B.1.351] Cov2 Pres Dtm-As03
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
Medroxyprogesterone acetate
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
MODERNA COVID-19 VACCINE RNA
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
METHOTREXATE
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
JNJ-78436735
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
Tozinameran
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
bnt162b2
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CC

Same molecule, other indications

Monomethyl Fumarate is also rated in:

Blood Stem Cell Transplant FailureDormant
BBB
Indicative ·
76 / 100
View asset →
Fanconi AnemiaDormant
BBB
Indicative ·
74 / 100
View asset →
Refractory Anemia With Excess BlastsDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →